drugset

drugset / Trial / NCT06029816

Neratinib Tablets in the Treatment of Advanced NSCLC With Rare EGFR Mutations

NCT06029816 ↗

Phase 2 Unknown 42 enrolled Convalife (Shanghai) Co., Ltd.

Non-randomizedParallel-groupOpen-labelTreatment

Summary

Single-arm, open-label, multicenter phase II clinical study

Timeline

Start: 2023-11-20
Primary completion: 2024-12-30
Completion: 2025-12-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Neratinib	Small molecule	—	—

Indications